Key result
Combination therapy alters CV outcomes and AKI risk in T2D and CKD.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Idowu et al. (2026) studied this question. Combination therapies in patients with type 2 diabetes and chronic kidney disease impact cardiovascular outcomes and the risk of acute kidney injury.
Synapse has enriched 10 related papers. Consider them for comparative context: